{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:41:07Z","timestamp":1791549667151,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:00:00Z","timestamp":1584662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NanOlogy-BDH, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Administration of chemotherapeutics as direct injections into tumors offers increased anti-tumor activity and reduced systemic toxicity. In this study, the Renca syngeneic murine xenograft model of renal cancer was used to evaluate the effects of intratumoral (IT) submicron particle docetaxel (NanoDoce\u00ae) on tumor growth and immunomodulation. Tumor volume (TV) was compared to controls, including intravenous (IV) chemotherapy. Flow cytometry of peripheral bloods and tumors was used to evaluate immune cell populations. Groups of animals were inoculated with a second Renca tumor at a site distant from the primary tumor. IT NanoDoce significantly reduced primary TV and reduced the growth rates of untreated secondary tumors. CD4+, CD8+ and Treg populations were increased in peripheral bloods from animals administered IT NanoDoce. Additional evaluation of the effect of IT NanoDoce on peripheral and local immune cell populations as well as the impact on sites of distant tumor growth are warranted.<\/jats:p>","DOI":"10.1007\/s10637-020-00922-5","type":"journal-article","created":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T11:02:57Z","timestamp":1584702177000},"page":"1618-1626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood"],"prefix":"10.1007","volume":"38","author":[{"given":"Holly A.","family":"Maulhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson M.","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gere S.","family":"diZerega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,20]]},"reference":[{"issue":"4","key":"922_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/cancers11040577","volume":"11","author":"HA Maulhardt","year":"2019","unstructured":"Maulhardt HA, Hylle L, Frost MV, Tornio A, Dafoe S, Drummond L, Quinn DI, Kamat AM, diZerega GS (2019) Local injection of submicron particle docetaxel is associated with tumor eradication, reduced systemic toxicity and an immunologic response in Uro-oncologic xenografts. Cancers 11(4):577. https:\/\/doi.org\/10.3390\/cancers11040577","journal-title":"Cancers"},{"key":"922_CR2","doi-asserted-by":"publisher","unstructured":"Verco J, Johnston W, Baltezor M, Kuehl PJ, Gigliotti A, Belinsky SA, Lopez A, Wolff R, Hylle L, diZerega G (2018) Pharmacokinetic profile of inhaled submicron particle paclitaxel (NanoPac((R))) in a rodent model. J Aerosol Med Pulm Drug Deliv. https:\/\/doi.org\/10.1089\/jamp.2018.1467","DOI":"10.1089\/jamp.2018.1467"},{"key":"922_CR3","doi-asserted-by":"publisher","unstructured":"Verco J, Johnston W, Frost M, Baltezor M, Kuehl PJ, Lopez A, Gigliotti A, Belinsky SA, Wolff R, diZerega G (2019) Inhaled submicron particle paclitaxel (NanoPac\u00ae) induces tumor regression and immune cell infiltration in an orthotopic athymic nude rat model of non-small cell lung cancer. J Aerosol Med Pulm Drug Deliv. https:\/\/doi.org\/10.1089\/jamp.2018.1517","DOI":"10.1089\/jamp.2018.1517"},{"issue":"11","key":"922_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206223","volume":"13","author":"JW Yu","year":"2018","unstructured":"Yu JW, Bhattacharya S, Yanamandra N, Kilian D, Shi H, Yadavilli S, Katlinskaya Y, Kaczynski H, Conner M, Benson W, Hahn A, Seestaller-Wehr L, Bi M, Vitali NJ, Tsvetkov L, Halsey W, Hughes A, Traini C, Zhou H, Jing J, Lee T, Figueroa DJ, Brett S, Hopson CB, Smothers JF, Hoos A, Srinivasan R (2018) Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS One 13(11):e0206223. https:\/\/doi.org\/10.1371\/journal.pone.0206223","journal-title":"PLoS One"},{"issue":"3","key":"922_CR5","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1158\/1078-0432.CCR-17-0186","volume":"24","author":"MJ O'Shaughnessy","year":"2018","unstructured":"O'Shaughnessy MJ, Murray KS, La Rosa SP, Budhu S, Merghoub T, Somma A, Monette S, Kim K, Corradi RB, Scherz A, Coleman JA (2018) Systemic antitumor immunity by PD-1\/PD-L1 inhibition is potentiated by vascular-targeted photodynamic therapy of primary tumors. Clin Cancer Res 24(3):592\u2013599. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0186","journal-title":"Clin Cancer Res"},{"issue":"6","key":"922_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","volume":"3","author":"SS Park","year":"2015","unstructured":"Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, Mansfield AS, Furutani KM, Olivier KR, Kwon ED (2015) PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res 3(6):610\u2013619. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0138","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"922_CR7","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1517\/17425247.2015.1014339","volume":"12","author":"M Elphick","year":"2015","unstructured":"Elphick M, von Hollen D, Pritchard JN, Nikander K, Hardaker LE, Hatley RH (2015) Factors to consider when selecting a nebulizer for a new inhaled drug product development program. Expert Opin Drug Deliv 12(8):1375\u20131387. https:\/\/doi.org\/10.1517\/17425247.2015.1014339","journal-title":"Expert Opin Drug Deliv"},{"issue":"Suppl 1","key":"922_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.urology.2003.09.052","volume":"62","author":"JA Eastham","year":"2003","unstructured":"Eastham JA, Kelly WK, Grossfeld GD, Small EJ, Cancer, Leukemia Group B (2003) Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62(Suppl 1):55\u201362","journal-title":"Urology"},{"issue":"9","key":"922_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183662","volume":"12","author":"DW Edwardson","year":"2017","unstructured":"Edwardson DW, Boudreau J, Mapletoft J, Lanner C, Kovala AT, Parissenti AM (2017) Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One 12(9):e0183662. https:\/\/doi.org\/10.1371\/journal.pone.0183662","journal-title":"PLoS One"},{"issue":"2","key":"922_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.yexcr.2017.12.018","volume":"362","author":"CR Millrud","year":"2018","unstructured":"Millrud CR, Mehmeti M, Leandersson K (2018) Docetaxel promotes the generation of anti-tumorigenic human macrophages. Exp Cell Res 362(2):525\u2013531. https:\/\/doi.org\/10.1016\/j.yexcr.2017.12.018","journal-title":"Exp Cell Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00922-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00922-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:47:24Z","timestamp":1678510044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00922-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,20]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["922"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00922-5","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,20]]},"assertion":[{"value":"17 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The following authors report holding a consultant\/advisory role, having stock ownership or receiving funding from NanOlogy, H.M., A.M., G.S.d.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The animal care and use program at Charles River Discovery Services, an Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited entity, performed animal handling and their Institutional Animal Care and use Committee (IACUC) approved this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}